JACKSONVILLE, Fla., June 21 /PRNewswire/ — Sinapis Pharma,
Inc. announces that its first patients were dosed in a Phase I
clinical trial study on June 14,
2010. This study, in human volunteers, is designed to
evaluate the safety, pharmacokinetics, and absolute bioavailability
of an intravenous infusion of methamphetamine. The first cohort,
investigating shorter infusion times, went well. Future cohorts
will evaluate longer infusion times and higher drug doses.
“We are excited to have launched the clinical development of
this drug with the objective of defining the exact dosing schedule
to take into a Phase II trial in traumatic brain injury or stroke,”
said Dr. Donald Picker, company CEO.
Sinapis hopes to be able to begin its important proof of
principle Phase II trial before year end.
Sinapis Pharma, Inc. (www.sinapispharma.com) is
an early stage biotechnology company whose lead compound
methamphetamine, as a low-dose intravenous infusion, has shown
remarkable pre-clinical efficacy in stroke and brain injury
models.
For more information contact Dr. Picker at
Don.Picker@gmail.com.
‘/>”/>
